Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.